Kaken Pharmaceutical , Ltd. Goodwill

The latest goodwill for 4521.T is $5.4B as of June 2026. That compares with $14B in the prior-year period — down 61.6% year over year. Investors often review this figure alongside Kaken Pharmaceutical , Ltd.'s historical trend and sector peers before judging valuation or financial health.

Over the past year, 4521.T's goodwill moved from $14B to $5.4B — a 61.6% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Kaken Pharmaceutical , Ltd.'s operating scale or balance-sheet position.

A goodwill figure of $5.4B for 4521.T is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting 4521.T's goodwill ($5.4B), review year-over-year change from $14B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.